“This is a coalition of the willing…I think all of you have to decide tomorrow when you go home, in your hospital how are you going to treat your patients if you’re doing cardiogenic shock angioplasty and balloon pump you will have a 50 percent survival and if that’s not good enough for you, then … Continue reading “Dr. Bill O’Neill: New Data from NCSI & Improving Outcomes in Cardiogenic Shock”
The use of mechanical circulatory support (MCS) in cardiogenic shock (CS) has been consistently shown to correlate with improved survival and assist interventionalists achieve complete revascularization.1,2,3 The use of MCS devices for the treatment of acute myocardial infarction complicated by cardiogenic shock (AMICS) may also provide hemodynamic support for some patients.4 Continue readingEarly Impella Support Associated with Increased Survival in Cardiogenic Shock
- This retrospective study evaluated observational data of patients receiving either early or delayed initiation of Impella for the management of acute myocardial infarction complicated by cardiogenic shock (AMICS).
- Receiving mechanical circulatory support (MCS) prior to percutaneous coronary intervention (PCI) compared with post-PCI initiation was associated with a higher survival rate to discharge among AMICS patients.
- Overall survival to discharge for the cohort was 44%.
- Additionally, early initiation of MCS at the first signs of shock and before inotropes, vasopressors, and PCI correlated with a higher rate of survival.
Reference: J Am Coll Cardiol 2018; 72:1972-80 Cardiogenic shock continues to be the leading cause of death in patients with acute myocardial infarction (AMI).1 Despite implementation of guideline-recommended early revascularization, mortality rates in AMI complicated by cardiogenic shock (AMICS) remains constant at about 50%. Given that about 60,000 patients with AMI develop CS every year,2 … Continue reading “Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care”
Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, discusses the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial. These results were presented at the American Heart Association Scientific Sessions 2018 in Chicago on Sunday, November 11. What did we learn from this pilot … Continue reading “The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial”
Video Chapters: The Impact of The Cardiogenic Shock Initiative (NCSI): One Year Later William O’Neill, MD Advances in the Treatment of Cardiovascular Disease in Women: PCI, MI, Shock, Myocarditis, SCAD, and Post-partum Cardiomyopathy Cindy Grines, MD Understanding the Importance of Ventricular Unloading in Management of AMI and Cardiogenic Shock Navin Kapur, MD Subscribe, or join the … Continue reading “National Cardiogenic Shock Initiative: 1 Year Later”
Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) database. The clinical publication highlights best practice protocols based on real-world evidence that is showing improved outcomes in cardiogenic shock. This clinical evidence is derived from Abiomed’s observational , commercial IQ database. In patients with AMICS receiving … Continue reading “Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device”
Dr. Bill O’Neill of Henry Ford Hospital and Dr. Ted Schreiber of Detroit Medical Center discuss updates on the Detroit Cardiogenic Shock Initiative (CSI). Partnering hospital systems participating in DCSI use a defined protocol for early placement of Impella in patients in cardiogenic shock. Since July, initial results from a small sampling of patients show … Continue reading “Updates on the Detroit Cardiogenic Shock Initiative: It’s Gone National”
For patients with cardiogenic shock (CS), intra-aortic balloon pump (IABP) had been an important tool for maintaining patients and improving survival after percutaneous coronary intervention (PCI). Randomized controlled trials, however, have found very little evidence to support the notion that IABP is helpful for reducing mortality or improving hemodynamics for patients with CS.1,2 The Impella® … Continue reading “IMPRESS in Severe Shock Trial: Looking Closer at the Data”
Data presented by Dr. William O’Neill of Henry Ford Hospital System at the 66th Annual Scientific Session of the American College of Cardiology also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented collaboration between five heart hospitals in Detroit, with the goal of determining whether outcomes in cardiogenic shock can be … Continue reading “Detroit Cardiogenic Shock Initiative: Initial Results”